 |
2 Diseases |  |
32 Trials |
|
32 Trials |  |
1662 News |  |
| «12...13141516171819202122232425» |
- ||||| Prevymis (letermovir) / Merck (MSD)
Clinical: #EBMT20Virtual CMV prophylaxis with Letermovir significantly reduces CMV post alloHCT in high risk patients (TCD, cordblood) @sloan_kettering #EBMT20 #btmsm 3/n https://t.co/JIyL8FqogQ (Twitter) - Aug 30, 2020
- || Prevymis (letermovir) / Merck (MSD)
Letermovir, anti CMV, con distinto perfil de toxicidad e interacciones @gedefo_sefh #EBMT20Virtual #5pharmacistday (Twitter) - Aug 29, 2020
- | Prevymis (letermovir) / Merck (MSD)
Journal: Letermovir in paediatric HSCT recipients. (Pubmed Central) - Aug 20, 2020
No abstract available
- cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis (aHSCT-in-MS): The Zurich Experience 24 Months after Approval () - Aug 16, 2020 - Abstract #MSDC2020MSDC_387;
Conditioning high-dose chemotherapy comprises BEAM-ATG, i.e. BCNU, etoposide, cytarabine, melphalan before- and ATG (d+1 and +2: 3.75 mg/kg/d) after stem cell re-transfusion (d0).Results 26 MS patients (13 females, 13 males) with a mean age of 40.8±7.8 years, mean disease duration of 8.9±4.8 years and a mean expanded disease status scale (EDSS) score of 5.0±1.2 have been treated with aHSCT...Although a substantial proportion of patients reported improvements of neurological functions and less fatigue, follow-up is too short to comment on long-term outcomes.Conclusions The safety profile of aHSCT-in-MS is acceptable, but requires vigilant monitoring and optimized antibacterial and antiviral prophylactic care. Regarding the increased risk of CMV reactivation (4/7 CMV-seropositive patients) and herpes zoster (2/26), we decided to establish prophylaxis with the CMV inhibitor letermovir in CMV-seropositive patients and to vaccinate all patients with Shingrix® after transplantation.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] Refractory and Resistant CMV Infections in Hematopoietic Cell Transplant Recipients in the Letermovir Primary Prophylaxis Era () - Aug 14, 2020 - Abstract #IDWeek2020IDWEEK_1949;
Regarding the increased risk of CMV reactivation (4/7 CMV-seropositive patients) and herpes zoster (2/26), we decided to establish prophylaxis with the CMV inhibitor letermovir in CMV-seropositive patients and to vaccinate all patients with Shingrix® after transplantation. Our study showed a strong association between primary prophylaxis with letermovir and reduction in refractory or resistant CMV infections and CMV disease in allo-HCT recipients.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] Reconstitution of CMV-specific cell-mediated immunity during letermovir prophylaxis in hematopoietic stem cell recipients () - Aug 14, 2020 - Abstract #IDWeek2020IDWEEK_1940;
High-risk patient populations can reconstitute CMV CMI while on letermovir. Ongoing investigation will help establish predictive parameters for CMV CMI that may allow risk stratification for CMV monitoring and letermovir usage.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] “Real world” Impact of Letermovir for Prevention of Cytomegalovirus Infection in Hematopoietic-Cell Transplantation () - Aug 14, 2020 - Abstract #IDWeek2020IDWEEK_829;
We demonstrated the “real-world” utility of LTM for CMV prevention in HCT recipients. Future studies should further evaluate the impact of LTM on antiviral drug usage, GVHD, and other transplant-related outcomes in this population.
- || PK/PD data, Journal: Pharmacokinetic Drug-Drug Interactions Between Letermovir and the Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, and Mycophenolate Mofetil. (Pubmed Central) - Aug 13, 2020
Given the increased exposures of cyclosporine, tacrolimus, and sirolimus, frequent monitoring of concentrations should be performed during administration and at discontinuation of letermovir, with dose adjustment as needed. These data support the reduction in clinical dosage of letermovir (to 240 mg) upon coadministration with cyclosporine.
- | Prevymis (letermovir) / Merck (MSD)
Trial completion date, Trial primary completion date: Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection (clinicaltrials.gov) - Aug 8, 2020
P2, N=32, Recruiting, Sponsor: Dana-Farber Cancer Institute
These data support the reduction in clinical dosage of letermovir (to 240 mg) upon coadministration with cyclosporine. Trial completion date: Jul 2021 --> Jul 2022 | Trial primary completion date: Dec 2020 --> Dec 2021
- | Tembexa (brincidofovir oral) / SymBio Pharma, Prevymis (letermovir) / Merck (MSD), maribavir (TAK-620) / Takeda, GSK
Journal: Resistant or refractory cytomegalovirus infections after hematopoietic cell transplantation: diagnosis and management. (Pubmed Central) - Aug 4, 2020
Many advances have been made to optimize future clinical trials for management of refractory or resistant CMV infections, and to better understand new resistance mechanisms to novel drugs. New drugs or strategies with limited toxicities are needed to improve outcomes of difficult to treat CMV infections in HCT recipients.
- || Prevymis (letermovir) / Merck (MSD)
Biomarker, Clinical, PK/PD data, Journal: Pharmacogenetic Analysis of OATP1B1, UGT1A1, and BCRP Variants in Relation to the Pharmacokinetics of Letermovir in Previously Conducted Clinical Studies. (Pubmed Central) - Jul 29, 2020
SLCO1B1 variant rs2306283, UGT1A1*28 TA promoter repeat, and BCRP variant rs2231142 had no effect on letermovir PK. Together, these data suggest that variants of enzymes and transporters that are involved in the disposition of letermovir in vitro may account for some variability in letermovir PK, but do not affect exposure to a clinically relevant extent.
- ||| Prevymis (letermovir) / Merck (MSD)
Clinical: Our #IDWeek2020 abstract "Combinatorial Polyfunctionality Analysis of Antigen-Specific T-cell Subsets (COMPASS) as a Predictor for Clinically Significant CMV Infection in the Letermovir Era" was accepted as an oral presentation! Yay! Wonder if they'll all be oral technically? 🤔 (Twitter) - Jul 24, 2020
- | Prevymis (letermovir) / Merck (MSD), maribavir (TAK-620) / Takeda, GSK
Preclinical, Journal: Placental transfer of Letermovir & Maribavir in the ex vivo human cotyledon perfusion model. New perspectives for in utero treatment of congenital cytomegalovirus infection. (Pubmed Central) - Jul 21, 2020
Together, these data suggest that variants of enzymes and transporters that are involved in the disposition of letermovir in vitro may account for some variability in letermovir PK, but do not affect exposure to a clinically relevant extent. Drugs' concentrations in the fetal side should be in the range for in utero treatment of fetuses infected with CMV as the mean FC was superior to the EC50 for both molecules.
- | Vistide (cidofovir) / Gilead
Journal, Combination therapy: Artemisone demonstrates synergistic antiviral activity in combination with approved and experimental drugs active against human cytomegalovirus. (Pubmed Central) - Jul 18, 2020
Importantly, the combination of artemisone with maribavir demonstrated synergistic antiviral activity ex-vivo, in a clinically-relevant multicellular model of human placental tissues maintained in organ culture. Our findings provide the basis for the use of artemisone in synergistically acting drug combinations, to enhance viral control and reduce antiviral drug toxicities.
- || Prevymis (letermovir) / Merck (MSD), tacrolimus / Generic mfg., Vistide (cidofovir) / Gilead
Clinical, Journal: Suppression of CMV Infection with Letermovir in a Kidney Transplant Patient. (Pubmed Central) - Jul 17, 2020
Furthermore, we observed significant drug interactions between letermovir and tacrolimus. Cytomegalovirus (CMV) disease with resistance to ganciclovir (GCV) is difficult to manage in transplant patients.Letermovir may become a new option for treatment and prophylaxis of GCV-resistant CMV infection, but assessment of treatment response is difficult.Letermovir may lead to drug interactions via CYP3A4.
- || Prevymis (letermovir) / Merck (MSD)
Clinical, Review, Journal: Letermovir and its role in the prevention of cytomegalovirus infection in seropositive patients receiving an allogeneic hematopoietic cell transplant. (Pubmed Central) - Jul 9, 2020
Letermovir is a novel agent that was approved for primary prophylaxis in CMV-seropositive adult allogeneic hematopoietic cell transplant recipients. This review focuses on letermovir's novel mechanism; clinical trials supporting its United States Food and Drug Administration (FDA) approval and subsequent follow-up analyses; clinical considerations, with an emphasis on pharmacology; and lessons learned from solid organ transplant recipients, as well as potential future directions.
- | Prevymis (letermovir) / Merck (MSD)
Journal: In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products. (Pubmed Central) - Jul 8, 2020
Several additional substitutions were detected in pUL56 and pUL89, and further characterization is needed to determine if any of these substitutions are clinically relevant. The analyses reported herein were conducted to confirm sponsor-reported drug-resistance pathways, to assess the frequency of resistance, and to better understand the risk of prophylaxis failures and treatment-emergent drug resistance.
- ||||| Prevymis (letermovir) / Merck (MSD), Foscavir (foscarnet) / Pfizer, Clinigen
Clinical: Case summary pt with CMV retinitis and stil low level viremia, what would you do now? 1-Continue letermovir 2- ask ophtho repear cMV pCR eye 3-CmV tcell immunity panel or 4-Foscarnet @FranciscoMarty_ @PergamIC @RazonableMD #EmoryID @janecyoon (Twitter) - Jul 8, 2020
- || Prevymis (letermovir) / Merck (MSD)
Clinical, Journal: Breakthrough cytomegalovirus pneumonia in hematopoietic stem cell transplant recipient on letermovir prophylaxis. (Pubmed Central) - Jul 7, 2020
The analyses reported herein were conducted to confirm sponsor-reported drug-resistance pathways, to assess the frequency of resistance, and to better understand the risk of prophylaxis failures and treatment-emergent drug resistance. No abstract available
- Campath (alemtuzumab) / Sanofi, tacrolimus / Generic mfg., doxycycline / Generic mfg., Pierre Fabre
[VIRTUAL] Disseminated Histoplasmosis in Lung Transplant Recipient Presenting as Hemophagocytic Lymphohistocytosis (ATS 2020 Virtual) - Jul 6, 2020 - Abstract #ATSI2020ATS-I_5878;
Tacrolimus was changed to cyclosporine...This case highlights the importance of bone marrow biopsy in the work-up for pancytopenia and infection remains a serious concern in lung transplant patient presenting with fever of unknown origin. It also raises the question; should all lung transplant donor and/or recipient be screened for histoplasmosis?
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] CMV-SPECIFIC FUNCTIONAL IMMUNE RECONSTITUTION IS SLOWER AFTER UMBILICAL CORD BLOOD COMPARED WITH MATCHED SIBLING DONOR HEMATOPOIETIC CELL TRANSPLANTATION (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_5881;
Our data suggest that CMV-specific functional immune reconstitution is slower within first year of HCT in CMV seropositive patients receiving UCB vs. PB MSD. Our findings support implementing strategies to suppress CMV reactivation such as letermovir and to accelerate immune reconstitution such as CMV-vaccines or CMV-specific T-cell adoptive transfer in CMV seropositive patients receiving UCB HCT.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] CMV-SPECIFIC FUNCTIONAL IMMUNE RECONSTITUTION IS SLOWER AFTER UMBILICAL CORD BLOOD COMPARED WITH MATCHED SIBLING DONOR HEMATOPOIETIC CELL TRANSPLANTATION (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_5880;
Our data suggest that CMV-specific functional immune reconstitution is slower within first year of HCT in CMV seropositive patients receiving UCB vs. PB MSD. Our findings support implementing strategies to suppress CMV reactivation such as letermovir and to accelerate immune reconstitution such as CMV-vaccines or CMV-specific T-cell adoptive transfer in CMV seropositive patients receiving UCB HCT.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] CMV-SPECIFIC FUNCTIONAL IMMUNE RECONSTITUTION IS SLOWER AFTER UMBILICAL CORD BLOOD COMPARED WITH MATCHED SIBLING DONOR HEMATOPOIETIC CELL TRANSPLANTATION (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_5879;
Our data suggest that CMV-specific functional immune reconstitution is slower within first year of HCT in CMV seropositive patients receiving UCB vs. PB MSD. Our findings support implementing strategies to suppress CMV reactivation such as letermovir and to accelerate immune reconstitution such as CMV-vaccines or CMV-specific T-cell adoptive transfer in CMV seropositive patients receiving UCB HCT.
- Actemra IV (tocilizumab) / Roche, JW Pharma, mycophenolate mofetil / Generic mfg., cyclosporine / Generic mfg.
[VIRTUAL] ADDITION OF TOCILIZUMAB TO CYCLOSPORINE-A AND MYCOPHENOLATE MOFETIL FOR GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS SIGNIFICANTLY ABROGATES SEVERE ACUTE GVHD AFTER DOUBLE-UNIT CORD BLOOD TRANSPLANTATION IN ADULTS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_5869;
P2
While many pts developed upper GI aGVHD, the marked reduction in lower GI aGVHD supports preferential reduction of T-cell homing to the lower gut. Investigation of this approach including aGVHD treatment responses, immune recovery & correlative biomarker/ microbiota studies are ongoing.
- Actemra IV (tocilizumab) / Roche, JW Pharma, mycophenolate mofetil / Generic mfg., cyclosporine / Generic mfg.
[VIRTUAL] ADDITION OF TOCILIZUMAB TO CYCLOSPORINE-A AND MYCOPHENOLATE MOFETIL FOR GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS SIGNIFICANTLY ABROGATES SEVERE ACUTE GVHD AFTER DOUBLE-UNIT CORD BLOOD TRANSPLANTATION IN ADULTS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_5868;
P2
While many pts developed upper GI aGVHD, the marked reduction in lower GI aGVHD supports preferential reduction of T-cell homing to the lower gut. Investigation of this approach including aGVHD treatment responses, immune recovery & correlative biomarker/ microbiota studies are ongoing.
- Actemra IV (tocilizumab) / Roche, JW Pharma, mycophenolate mofetil / Generic mfg., cyclosporine / Generic mfg.
[VIRTUAL] ADDITION OF TOCILIZUMAB TO CYCLOSPORINE-A AND MYCOPHENOLATE MOFETIL FOR GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS SIGNIFICANTLY ABROGATES SEVERE ACUTE GVHD AFTER DOUBLE-UNIT CORD BLOOD TRANSPLANTATION IN ADULTS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_5867;
P2
While many pts developed upper GI aGVHD, the marked reduction in lower GI aGVHD supports preferential reduction of T-cell homing to the lower gut. Investigation of this approach including aGVHD treatment responses, immune recovery & correlative biomarker/ microbiota studies are ongoing.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] CMV SEROPOSITIVITY DRIVES T CELL RECONSTITUTION AFTER CD34-SELECTED ALLOGENEIC HCT DESPITE REDUCTION OF VIREMIA WITH LETERMOVIR (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_5004;
To our knowledge, these are the first data to indicate that prior CMV exposure exerts effects on T-cell reconstitution independent of quantifiable viremia. Further investigation into the mechanisms underlying these findings will shed greater light on the complexity of the interaction between CMV and host T-cell response and, perhaps, inform the development of future adoptive cell therapy approaches.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] CMV SEROPOSITIVITY DRIVES T CELL RECONSTITUTION AFTER CD34-SELECTED ALLOGENEIC HCT DESPITE REDUCTION OF VIREMIA WITH LETERMOVIR (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_5003;
To our knowledge, these are the first data to indicate that prior CMV exposure exerts effects on T-cell reconstitution independent of quantifiable viremia. Further investigation into the mechanisms underlying these findings will shed greater light on the complexity of the interaction between CMV and host T-cell response and, perhaps, inform the development of future adoptive cell therapy approaches.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] CMV SEROPOSITIVITY DRIVES T CELL RECONSTITUTION AFTER CD34-SELECTED ALLOGENEIC HCT DESPITE REDUCTION OF VIREMIA WITH LETERMOVIR (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_5002;
To our knowledge, these are the first data to indicate that prior CMV exposure exerts effects on T-cell reconstitution independent of quantifiable viremia. Further investigation into the mechanisms underlying these findings will shed greater light on the complexity of the interaction between CMV and host T-cell response and, perhaps, inform the development of future adoptive cell therapy approaches.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] USE OF LETERMOVIR IN OFF-LABEL INDICATIONS: INFECTIOUS DISEASES WORKING PARTY EBMT RETROSPECTIVE STUDY (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4959;
The efficacy of the use of LMV as secondary prophylaxis was high. The preliminary experience with the use of LMV for treatment of patients with refractory/resistant CMV infection/disease showed good short-term effect.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] USE OF LETERMOVIR IN OFF-LABEL INDICATIONS: INFECTIOUS DISEASES WORKING PARTY EBMT RETROSPECTIVE STUDY (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4958;
The efficacy of the use of LMV as secondary prophylaxis was high. The preliminary experience with the use of LMV for treatment of patients with refractory/resistant CMV infection/disease showed good short-term effect.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] USE OF LETERMOVIR IN OFF-LABEL INDICATIONS: INFECTIOUS DISEASES WORKING PARTY EBMT RETROSPECTIVE STUDY (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4957;
The efficacy of the use of LMV as secondary prophylaxis was high. The preliminary experience with the use of LMV for treatment of patients with refractory/resistant CMV infection/disease showed good short-term effect.
- [VIRTUAL] EPIDEMIOLOGY, RISK FACTORS AND OUTCOMES OF CMV INFECTION IN ADULTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT (HCT): A SINGLE INSTITUTIONAL COHORT STUDY (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4956;
From a retrospective cohort of 1,283 seropositive adults who underwent HCT at Stanford University from January 2009 to May 2019, we analyzed 1,107 adults after the exclusion of patients on letermovir (N=78), who received a second HCT (N=78), or were not screened (N=8)...From 2015-2017 umbilical cord blood (UCB) recipients received valacyclovir 2000 mg thrice daily...Median overall antiviral exposure through D+100 was 30 days (range 0-100); ganciclovir (54%) was the most common initial agent used [median exposure 24 days (range 1-92)] vs 39% valganciclovir [median 25d (1-93d)] vs 7% foscarnet [median 10d (0-53d)]... Despite effective preemptive therapy strategies, CMV infection remains a significant and common complication of HCT and to have a measurable impact on patients and healthcare system.
- [VIRTUAL] EPIDEMIOLOGY, RISK FACTORS AND OUTCOMES OF CMV INFECTION IN ADULTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT (HCT): A SINGLE INSTITUTIONAL COHORT STUDY (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4955;
From a retrospective cohort of 1,283 seropositive adults who underwent HCT at Stanford University from January 2009 to May 2019, we analyzed 1,107 adults after the exclusion of patients on letermovir (N=78), who received a second HCT (N=78), or were not screened (N=8)...From 2015-2017 umbilical cord blood (UCB) recipients received valacyclovir 2000 mg thrice daily...Median overall antiviral exposure through D+100 was 30 days (range 0-100); ganciclovir (54%) was the most common initial agent used [median exposure 24 days (range 1-92)] vs 39% valganciclovir [median 25d (1-93d)] vs 7% foscarnet [median 10d (0-53d)]... Despite effective preemptive therapy strategies, CMV infection remains a significant and common complication of HCT and to have a measurable impact on patients and healthcare system.
- [VIRTUAL] EPIDEMIOLOGY, RISK FACTORS AND OUTCOMES OF CMV INFECTION IN ADULTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT (HCT): A SINGLE INSTITUTIONAL COHORT STUDY (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4954;
From a retrospective cohort of 1,283 seropositive adults who underwent HCT at Stanford University from January 2009 to May 2019, we analyzed 1,107 adults after the exclusion of patients on letermovir (N=78), who received a second HCT (N=78), or were not screened (N=8)...From 2015-2017 umbilical cord blood (UCB) recipients received valacyclovir 2000 mg thrice daily...Median overall antiviral exposure through D+100 was 30 days (range 0-100); ganciclovir (54%) was the most common initial agent used [median exposure 24 days (range 1-92)] vs 39% valganciclovir [median 25d (1-93d)] vs 7% foscarnet [median 10d (0-53d)]... Despite effective preemptive therapy strategies, CMV infection remains a significant and common complication of HCT and to have a measurable impact on patients and healthcare system.
- [VIRTUAL] LETERMOVIR AS PRE-EMPTIVE THERAPY FOR RESISTANT CYTOMEGALOVIRUS INFECTION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4066;
In the reported case, after trying all the approved therapeutic options, letermovir was the only antiviral that achieved an effective and long-lasting response despite multiple episodes of GvHD that needed adjustment of the inmunosupressive therapy. In the setting of clinical resistance or when the drug is not used as prophylaxis, letermovir can lead to an optimal control of CMV DNAemia with a safety profile.
- [VIRTUAL] LETERMOVIR AS PRE-EMPTIVE THERAPY FOR RESISTANT CYTOMEGALOVIRUS INFECTION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4065;
In the reported case, after trying all the approved therapeutic options, letermovir was the only antiviral that achieved an effective and long-lasting response despite multiple episodes of GvHD that needed adjustment of the inmunosupressive therapy. In the setting of clinical resistance or when the drug is not used as prophylaxis, letermovir can lead to an optimal control of CMV DNAemia with a safety profile.
- [VIRTUAL] LETERMOVIR AS PRE-EMPTIVE THERAPY FOR RESISTANT CYTOMEGALOVIRUS INFECTION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4064;
In the reported case, after trying all the approved therapeutic options, letermovir was the only antiviral that achieved an effective and long-lasting response despite multiple episodes of GvHD that needed adjustment of the inmunosupressive therapy. In the setting of clinical resistance or when the drug is not used as prophylaxis, letermovir can lead to an optimal control of CMV DNAemia with a safety profile.
- Prevymis (letermovir) / Merck (MSD), Foscavir (foscarnet) / Pfizer, Clinigen, Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe
[VIRTUAL] USE OF CMV-HYPERIMMUNE GLOBULINS (CMV-HYG) AS PRE-EMPTIVE THERAPY OR TREATMENT OF CMV INFECTION IN HSCT RECIPIENTS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4051;
Our preliminary data indicate that the use of CMV-HyG in combination with antiviral therapy in patients with multiple CMV reactivations, and in patients with CMV disease might contribute to an optimal control of the infection. Further prospective studies including a large number of patients are needed to confirm our results.
- Prevymis (letermovir) / Merck (MSD), Foscavir (foscarnet) / Pfizer, Clinigen, Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe
[VIRTUAL] USE OF CMV-HYPERIMMUNE GLOBULINS (CMV-HYG) AS PRE-EMPTIVE THERAPY OR TREATMENT OF CMV INFECTION IN HSCT RECIPIENTS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4050;
Our preliminary data indicate that the use of CMV-HyG in combination with antiviral therapy in patients with multiple CMV reactivations, and in patients with CMV disease might contribute to an optimal control of the infection. Further prospective studies including a large number of patients are needed to confirm our results.
- Prevymis (letermovir) / Merck (MSD), Foscavir (foscarnet) / Pfizer, Clinigen, Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe
[VIRTUAL] USE OF CMV-HYPERIMMUNE GLOBULINS (CMV-HYG) AS PRE-EMPTIVE THERAPY OR TREATMENT OF CMV INFECTION IN HSCT RECIPIENTS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4049;
Our preliminary data indicate that the use of CMV-HyG in combination with antiviral therapy in patients with multiple CMV reactivations, and in patients with CMV disease might contribute to an optimal control of the infection. Further prospective studies including a large number of patients are needed to confirm our results.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] RISK FACTORS FOR CMV REACTIVATION AND DISEASE AMONG HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS - DEFINING THE TARGET POPULATION FOR LETERMOVIR PROPHYLAXIS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4027;
Pre-emptive treatment with antivirals and CMV specific IgG is highly effective. CMV disease is rare and almost exclusively associated with severe GvHD.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] RISK FACTORS FOR CMV REACTIVATION AND DISEASE AMONG HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS - DEFINING THE TARGET POPULATION FOR LETERMOVIR PROPHYLAXIS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4026;
Pre-emptive treatment with antivirals and CMV specific IgG is highly effective. CMV disease is rare and almost exclusively associated with severe GvHD.
- Prevymis (letermovir) / Merck (MSD)
[VIRTUAL] RISK FACTORS FOR CMV REACTIVATION AND DISEASE AMONG HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS - DEFINING THE TARGET POPULATION FOR LETERMOVIR PROPHYLAXIS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4025;
Pre-emptive treatment with antivirals and CMV specific IgG is highly effective. CMV disease is rare and almost exclusively associated with severe GvHD.
- Prevymis (letermovir) / Merck (MSD), tacrolimus / Generic mfg., cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] VERSATILE EFFECTS OF LETERMOVIR PROPHYLAXIS FOR CYTOMEGALOVIRUS ON ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-INSTITUTION ANALYSIS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3997;
GVHD prophylaxis consisted of tacrolimus and short-term methotrexate with or without low-dose anti-thymocyte globulin... The result of this study suggested that prophylactic use of LET might reduce TRM via not only suppression of CMV disease but also reduction of CMV-indirectly-related complications such as clinically significant acute GVHD.
- Prevymis (letermovir) / Merck (MSD), tacrolimus / Generic mfg., cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] VERSATILE EFFECTS OF LETERMOVIR PROPHYLAXIS FOR CYTOMEGALOVIRUS ON ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-INSTITUTION ANALYSIS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3996;
GVHD prophylaxis consisted of tacrolimus and short-term methotrexate with or without low-dose anti-thymocyte globulin... The result of this study suggested that prophylactic use of LET might reduce TRM via not only suppression of CMV disease but also reduction of CMV-indirectly-related complications such as clinically significant acute GVHD.
- Prevymis (letermovir) / Merck (MSD), tacrolimus / Generic mfg., cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] VERSATILE EFFECTS OF LETERMOVIR PROPHYLAXIS FOR CYTOMEGALOVIRUS ON ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-INSTITUTION ANALYSIS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3995;
GVHD prophylaxis consisted of tacrolimus and short-term methotrexate with or without low-dose anti-thymocyte globulin... The result of this study suggested that prophylactic use of LET might reduce TRM via not only suppression of CMV disease but also reduction of CMV-indirectly-related complications such as clinically significant acute GVHD.
- valacyclovir / Generic mfg.
[VIRTUAL] HIGH DOSE VALACICLOVIR AS CMV PROPHYLAXIS IN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3973;
This may reduce requirement for myelotoxic CMV treatment and inpatient hospital admission. CMV infection following HDvala cessation remains a risk, and ongoing monitoring is required.
- valacyclovir / Generic mfg.
[VIRTUAL] HIGH DOSE VALACICLOVIR AS CMV PROPHYLAXIS IN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3972;
This may reduce requirement for myelotoxic CMV treatment and inpatient hospital admission. CMV infection following HDvala cessation remains a risk, and ongoing monitoring is required.
- valacyclovir / Generic mfg.
[VIRTUAL] HIGH DOSE VALACICLOVIR AS CMV PROPHYLAXIS IN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3971;
This may reduce requirement for myelotoxic CMV treatment and inpatient hospital admission. CMV infection following HDvala cessation remains a risk, and ongoing monitoring is required.